Get started
Anixa Biosciences, Inc.Anixa Biosciences, Inc.Anixa Biosciences, Inc.

Anixa Biosciences, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

ANIX chart


Full chart

ANIX upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪117.78 M‬USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.39USD
Net income (FY)
‪−9.81 M‬USD
Revenue (FY)
‪210.00 K‬USD
Shares float
‪30.55 M‬
Beta (1Y)
0.01

Employees


Employees (FY)
5
Change (1Y)
0
Revenue / Employee (1Y)
‪42.00 K‬USD
Net income / Employee (1Y)
‪−1.96 M‬USD

About Anixa Biosciences, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Amit D. Kumar
Website
anixa.com
Headquarters
San Jose
Founded
1982
FIGI
BBG000BG3J79
Anixa Biosciences, Inc. is a biotechnology company, which engages in the development of therapies and vaccines focused on oncology and infectious disease. It operates through the following segments: CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics, and Other. The CAR-T Therapeutics segment involves the development of immuno-therapy drugs against cancer. The Cancer Vaccines segment includes the early stages development of immunization for breast and ovarian cancer. The company was founded on November 5, 1982 and is headquartered San Jose, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

Ideas



See all ideas 

ANIX news



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Sparks


Curated watchlists where ANIX is featured.

See all sparks 

Frequently Asked Questions


The current price of ANIX is 3.45 USD — it has increased by 4.57% in the past 24 hours. Watch Anixa Biosciences, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Anixa Biosciences, Inc. stocks are traded under the ticker ANIX.
ANIX stock has risen by 16.19% compared to the previous week, the month change is a 17.31% rise, over the last year Anixa Biosciences, Inc. has showed a 10.22% increase.
We've gathered analysts' opinions on Anixa Biosciences, Inc. future price: according to them, ANIX price has a max estimate of 10.00 USD and a min estimate of 7.00 USD. Watch ANIX chart and read a more detailed Anixa Biosciences, Inc. stock forecast: see what analysts think of Anixa Biosciences, Inc. and suggest that you do with its stocks.
ANIX reached its all-time high on Jul 7, 1993 with the price of 259.38 USD, and its all-time low was 0.60 USD and was reached on Aug 15, 2017. View more price dynamics on ANIX chart.
See other stocks reaching their highest and lowest prices.
ANIX stock is 7.33% volatile and has beta coefficient of 0.01. Track Anixa Biosciences, Inc. stock price on the chart and check out the list of the most volatile stocks — is Anixa Biosciences, Inc. there?
Today Anixa Biosciences, Inc. has the market capitalization of ‪117.78 M‬, it has increased by 13.97% over the last week.
Yes, you can track Anixa Biosciences, Inc. financials in yearly and quarterly reports right on TradingView.
Anixa Biosciences, Inc. is going to release the next earnings report on Jan 1, 2025. Keep track of upcoming events with our Earnings Calendar.
ANIX earnings for the last quarter are −0.10 USD per share, whereas the estimation was −0.09 USD resulting in a −18.94% surprise. The estimated earnings for the next quarter are −0.09 USD per share. See more details about Anixa Biosciences, Inc. earnings.
Anixa Biosciences, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
ANIX net income for the last quarter is ‪−3.28 M‬ USD, while the quarter before that showed ‪−3.14 M‬ USD of net income which accounts for −4.40% change. Track more Anixa Biosciences, Inc. financial stats to get the full picture.
No, ANIX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 5, 2024, the company has 5.00 employees. See our rating of the largest employees — is Anixa Biosciences, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Anixa Biosciences, Inc. EBITDA is ‪−13.68 M‬ USD, and current EBITDA margin is ‪−5.22 K‬%. See more stats in Anixa Biosciences, Inc. financial statements.
Like other stocks, ANIX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Anixa Biosciences, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Anixa Biosciences, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Anixa Biosciences, Inc. stock shows the sell signal. See more of Anixa Biosciences, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.